ScreenPro Security Ltd. |Twitter
  • ScreenPro’s (SCRN) wholly-owned subsidiary, Naturevan Nutrition, will expand distribution of its products to Japan and South Korea
  • This will allow the company to expand supply to a larger audience and enter into different distribution channels, multiplying sales and profit
  • Naturevan provides natural health supplements and products that are made in Canada and distributed for sale online
  • ScreenPro is a medical technology company that provides turnkey screening solutions with its proprietary medical alerting software
  • ScreenPro Security Inc. (SCRN) is up 16.67 per cent, trading at C$0.035 per share at 3:30 pm ET

ScreenPro’s (SCRN) wholly-owned subsidiary, Naturevan Nutrition, will expand the distribution of its products to Japan and South Korea.

Management is currently working on distribution agreements in Asia. This will allow the company to expand supply to a larger audience and enter into different distribution channels, multiplying sales and profit.

Naturevan has a unique set of products that are tailored to various audiences. Naturevan’s line of diversified products offers popular health supplements in both North America and Asia. It carries many top-selling Asian vitamin products such as Cissus Plus, Albumin Max, and Milk Thistle Liver Care.

South Korea has a growing marketplace for supplements that welcomes the success of Naturevan distribution. The South Korean vitamin market is expected to grow annually by 5.53 per cent between 2022-2027. With the growing market, the company foresees distribution into the Asian marketplace to be highly successful.

ScreenPro is a medical technology company that provides turnkey screening solutions with its proprietary medical alerting software. The company recently introduced Naturevan Nutrition Ltd. to its portfolio. Naturevan provides natural health supplements and products that are made in Canada and distributed for sale online.

ScreenPro Security Inc. (SCRN) is up 16.67 per cent, trading at C$0.035 per share at 3:30 pm ET.


More From The Market Online

Canadian biotech stock investigates potential weight loss drugs

FSD Pharma Inc. (CSE:HUGE) is expanding its pipeline into metabolic and related disorders including weight loss and liver health.
The Market Online Video

Emerging opportunity in a growing, high-value dermatological market

Kane Biotech (TSXV:KNE) engages in the development and commercialization of products that prevent and remove microbial biofilms.